Atrial Fibrillation Trial, Recruiting NCT06019845 Sponsor: Stereotaxis Condition: Atrial Fibrillation
Back to Atrial Fibrillation

Atrial Fibrillation Trial, Recruiting

NCT06019845
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older at the time of signing consent
  • People who have a heart rhythm problem (affecting the upper or lower chambers of the heart) that has been recorded on a heart monitor test within the past 12 months, and for whom an ablation procedure is recommended based on established European heart rhythm guidelines
  • People who can safely be near or exposed to magnetic fields
  • People who are able and willing to attend follow-up visits at the study site for up to 12 months
  • People who are willing and able to give their informed consent to participate

Who may not be able to join:

  • People who have an implanted device that is not safe around magnetic fields, or a device that cannot be safely removed before the procedure
  • People who are unable to lie flat on their back comfortably or without their blood pressure becoming unstable for an extended period of time
  • People who weigh more than 200 kg (the maximum weight the procedure table can support)
  • Women of childbearing age who are pregnant, plan to become pregnant during the study, or who do not have a negative pregnancy test result
  • People who have had a blood clot inside the heart within the past 12 weeks
  • People where the study device (MAGiC) would need to pass across an artificial (prosthetic) heart valve
  • Cases where the study device would be used in the coronary arteries (the blood vessels that supply the heart muscle)
  • People with a known history of reactions or allergies to foreign objects, or who have severe allergies
  • People who currently have an acute illness or an active infection anywhere in the body
  • People with tissue or structural abnormalities that may increase the risk of complications after the procedure, including a reduced ability to fight infection
  • People who cannot receive heparin (a blood-thinning medication) or a suitable alternative to prevent blood clotting during the procedure
  • People who have had a heart attack within the past 6 weeks
  • People who have had heart surgery within the past 8 weeks
  • People experiencing unstable chest pain (unstable angina) at the time of enrolment
  • People who have had a stroke, mini-stroke (TIA), or a blood clot travelling to another part of the body within the past 30 days
  • People who have had a previous heart ablation procedure within the past 30 days
  • People who have had an electrical heart ablation procedure within the past 6 weeks
  • People whose doctor estimates their life expectancy to be less than 12 months
  • People who are currently participating, or who have participated within the past 30 days, in another interventional clinical trial
  • People with significant uncontrolled or unstable health conditions that, in the investigator's opinion, would prevent them from completing the study
  • People whom the investigator considers ineligible for any other reason

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Betsy Lowry, Stereotaxis

Phone: 9737236613

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Stereotaxis
Registry
ClinicalTrials.gov
Start date
2 January 2024
Est. completion
31 December 2027

Where this trial is recruiting

🇩🇰 Denmark 🇱🇹 Lithuania 🇳🇱 Netherlands 🇵🇱 Poland

Primary endpoints

Acute Performance; Acute Safety

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov